The advanced AI, now offered on the Exo Iris system, offers instant feedback as a user sweeps the handheld ultrasound through an organ. It automatically identifies optimal imaging and provides diagnostic insights in real-time without internet or cloud reliance.
Exo first unveiled its Iris device for versatile imaging performance in point-of-care ultrasound (POCUS) in September 2023. Earlier this year, it launched its FDA-cleared cardiac and lung AI applications for the handheld ultrasound device.
With SweepAI, the company now offers automated AI-based indicators for congestive heart failure, detection of acute decompensated heart failure, stroke volume and heart rate and determination of left ventricular wall hypertrophy.
“What sets SweepAI apart is its seamless feedback in allowing you to navigate to the right views with minimal cognitive overload,” said Dornoosh Zonoobi, VP of AI at Exo. “With built-in auto-capture tools that monitor your scanning session, you don’t need to start over if a patient moves. Our AI simplifies the process, ensuring accurate, dependable results every time.”
Exo also introduced its new offering, Exo U. The on-device education platform offers quick, engaging lessons for learning ultrasound. The company added new software upgrades and features for Iris and its Works platform, too. They now include auto-color, auto-doppler, auto-eFAST, OB measurements package and more.
“You won’t find another ultrasound company innovating this fast,” said Sandeep Akkaraju, Co-founder and CEO at Exo. “SweepAI and the continuous improvements to Exo Iris set a new standard for confidence and ease in ultrasound scanning.”
